The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials

The main aim of the current study was to summarize the findings of available clinical studies to assess nano-curcumin's influence on COVID patients. A comprehensive online search was performed in Scopus, PubMed, ISI Web of Science, and Google Scholar until March 2022 to identify trials that investigated the effects of nano-curcumin in patients with COVID-19. Eight studies comprising 569 patients were included in this review. Compared with placebo, nano-curcumin had no significant effect on C-reactive protein (CRP) and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6). However, gene expression of IL-6 and gene expression as well as secretion of interleukin-1 beta (IL-1 beta) significantly decreased following nano-curcumin intervention. Nano-curcumin had beneficial effects on fever, cough, chills, myalgia, and olfactory and taste disturbances. The duration of hospitalization and mortality rate were significantly lower in the nano-curcumin group compared with the control group. Lymphocyte count was significantly increased after curcumin supplementation. Nano-curcumin also had favorable effects on O-2 saturation, sputum, chest pain, wheeze, and dyspnea in patients with COVID-19. No major adverse effects were reported in response to nano-curcumin supplementation. In summary, the results of this systematic review of clinical trials suggested that nano-curcumin supplementation has beneficial effects on inflammation, respiratory function, disease manifestations, and complications in patients with COVID-19 viral infection.

Automated summary

The aim of this study was to summarize the findings of clinical studies on the effects of nano-curcumin on COVID-19 patients. A comprehensive search was conducted to identify relevant trials, and a total of eight studies with 569 patients were included. Nano-curcumin did not have a significant effect on certain inflammatory markers, but it significantly decreased the gene expression of IL-6 and IL-1 beta. It had beneficial effects on symptoms and outcomes, including fever, cough, chills, myalgia, hospitalization duration, mortality rate, lymphocyte count, O-2 saturation, sputum, chest pain, wheeze, and dyspnea in COVID-19 patients. No major adverse effects were reported.